Radiation-induced thyroid stunning: Differential effects of 123I, 131I, 99mTc, and 211At on iodide transport and NIS mRNA expression in cultured thyroid cells

Journal of Nuclear Medicine

Volumn 50, Issue 7, 2009, Pages 1161-1167

  Lundh, Charlotta ^a   Lindencrona, Ulrika ^a   Postgård, Per ^a   Carlsson, Therese ^b   Nilsson, Mikael ^b   Forssell Aronsson, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

123I; 131I; 211At; 99mTc; NIS; Thyroid stunning

Indexed keywords

ASTATINE 211; IODIDE; IODINE 123; IODINE 131; MESSENGER RNA; RADIOISOTOPE; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; THYROTROPIN;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; IODINE 131 UPTAKE TEST; IRRADIATION; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CELL; THYROID DISEASE; THYROID STUNNING; TSH SECRETING CELL;

ANIMALS; ASTATINE; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE EXPRESSION REGULATION; IODINE; IODINE RADIOISOTOPES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RNA, MESSENGER; SWINE; SYMPORTERS; TECHNETIUM; THYROID DISEASES; THYROID GLAND;

EID: 67650093752     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.061150     Document Type: Article

References (40)

1. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Int J Rad Appl Instrum B. 1986;13:277-279.
2. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun. 1997;18:505-512.
3. 131I on postsurgical thyroid remnants. J Nucl Med. 2000;41:2038-2042.
4. 131I therapeutic efficacy is not in-fluenced by stunning after diagnostic whole-body scanning. Radiology. 2004;232:527-533.
5. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning." Nucl Med Commun. 2004;25:883-889.
6. 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619-625.
7. 123I. Eur J Nucl Med Mol Imaging. 2002;29:783-788.
8. Sisson JC, Avram AM, Lawson SA, Gauger PG, Doherty GM. The so-called stunning of thyroid tissue. J Nucl Med. 2006;47:1406-1412.
9. 131I irradiation in cultured thyroid epithelial cells. J Nucl Med. 2002;43:828-834.
10. 131I in vitro. J Nucl Med. 2007;48:481-486.
11. 131I-induced thyroid stunning. Cancer Res. 2007;67:7512-7517.
12. 131I scans. Nucl Med Commun. 2004;25:129-134.
13. Urhan M, Dadparvar S, Mavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging. 2007;34:1012-1017.
14. 125I- transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nucl Med Biol. 2001;28:41-50.
15. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med. 2004;45:500-507.
16. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000;6:1433-1455.
17. 125I- in nude mice bearing tumors derived fromanaplastic thyroid carcinoma cell lines. Cancer Biother Radiopharm. 2006;21:591-600.
18. 211At]astatide in NIS-transfected human cancer cells. Nucl Med Biol. 2002;29:729-739.
19. R). Kidlington, U.K.: International Commission on Radiological Protection; 2003.
20. Lindegren S, Bäck T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157-160.
21. Salvat F, Fernández-Varea JM, Acosta E, Sempau J. PENELOPE: A Code System for Monte Carlo Simulation of Electron and Photon Transport. Issy-les-Moulineaux, France: OECD Nuclear Energy Agency; 2001.
22. Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD: Radionuclide Data and Decay Schemes. Reston, VA: Society of Nuclear Medicine; 1989.
23. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36.
24. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980;102:344-352.
25. R values of Auger emitters and low-range beta emitters with particular reference to tritium. J Radiol Prot. 2007;27:157-168.
26. 211At treated mice. Health Phys. 1984;46:377-383.
27. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of astatine-211 decay. Radiat Res. 1986;105:27-36.
28. Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry. Int J Radiat Biol. 2000;76:1129-1141.
29. 211At and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. Anticancer Res. 1998;18:1671-1676.
30. 211At-monoclonal antibody compared to external irradiation on two human cancer cell lines. Anticancer Res. 2000;20:1005-1012.
31. 60Co irradiation in nude mice. J Nucl Med. 2005;46:464-471.
32. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an a-emitter in vivo. J Nucl Med. 2005;46:2061-2067.
33. 211At for double-strand break induction in human fibroblasts. Radiat Res. 2007;167:312-318.
34. 125I-in thyroid epithelial cells: effects of anion channel blocker 4,4′-diisothiocyanostilbene-2,2′-disulfonic acid on apical efflux and cellular retention. Nucl Med Biol. 2007;34:523-530.
35. Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/ iodide symporter by thyrotropin. J Biol Chem. 2001;276:21458-21463.
36. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242-246.
37. Park H-M, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49-54.
38. Klein HA, DiSibio KJ, Sims D, Singleton HC, Worthy LJ. I-123 whole body scanning: case report and discussion. Clin Nucl Med. 2005;30:312-316.
39. 131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007;48:1043-1046.
40. Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide in man: refinement of current ICRP dosimetry models. Cancer Biother Radiopharm. 2003;18:445-450.